Background: Numerous currently incurable human diseases have been causally linked to mutations in connexin (Cx) genes. In several instances, pathological mutations generate abnormally active Cx hemichannels, referred to also as “leaky” hemichannels. The goal of this study was to assay the in vivo efficacy of a potent antagonist antibody targeting Cx hemichannels. Methods: We employed the antibody to treat Cx3

A potent antagonist antibody targeting connexin hemichannels alleviates Clouston syndrome symptoms in mutant mice

Ziraldo Gaia;Peres Chiara;Nardin Chiara;Salvatore Anna Maria;Chiani Francesco;Scavizzi Ferdinando;Raspa Marcello;Mammano Fabio
2020

Abstract

Background: Numerous currently incurable human diseases have been causally linked to mutations in connexin (Cx) genes. In several instances, pathological mutations generate abnormally active Cx hemichannels, referred to also as “leaky” hemichannels. The goal of this study was to assay the in vivo efficacy of a potent antagonist antibody targeting Cx hemichannels. Methods: We employed the antibody to treat Cx3
2020
Istituto di Biochimica e Biologia Cellulare - IBBC - Sede Secondaria Monterotondo
Antibody drug discovery
Genodermatosis
Epidermis
Sebocytes
Calcium
ATP
File in questo prodotto:
File Dimensione Formato  
main (1).pdf

accesso aperto

Licenza: Creative commons
Dimensione 3.6 MB
Formato Adobe PDF
3.6 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/420850
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 21
social impact